Show Notes
"Isn't microdosing just placebo effect??" You may have heard this before but is it true?
Dr. Zachary Walsh, a leading clinical psychologist and researcher, explores the therapeutic potential of psychedelics in this episode, focusing on psilocybin-assisted psychotherapy for opioid titration and his involvement in the Microdose.me study.
He explains the distinction between cannabis, used for symptom relief, and psychedelics and discusses the controversial link between cannabis and psychosis, emphasizing the need for further research.
Join us as he shares insights on the evolving role of clinicians in supporting patients interested in microdosing and the challenges of integrating psychedelic medicine into healthcare!
Donate to MAPS Canada at https://mapscanada.org/donate/ Support MAPS Canada Podcast
More from MAPS Canada Podcast
Healing is often understood through the individual experience, but what might we learn by centring Indigenous perspectives on the deeply relational nature of psychedelic healing?
How can we better support Indigenous access to psychedelic-assisted healing, develop community-led models of care, and shape the future of psychedelic research in Canada?
What happens when psychedelic research moves beyond the traditional pharmaceutical model and becomes more patient-centred, grassroots, and responsive to the realities of how people are actually accessing these therapies?
What can we learn about psychedelics by studying how people actually use them in the real world?
In this episode of the MAPS Canada Podcast, host Matt Hamel speaks with occupational therapist Shel Scott about the emerging role of psychedelic-assisted therapy in the treatment of eating disorders. Drawing from her unique perspective as both an eating disorder survivor and a mental health clinician, Shel explores why eating disorders remain among the most challenging psychiatric conditions to treat, and where psychedelic medicines may offer new therapeutic possibilities.